ATE78169T1 - Behandlung von diabetes durch kombinierte insulinformen. - Google Patents
Behandlung von diabetes durch kombinierte insulinformen.Info
- Publication number
- ATE78169T1 ATE78169T1 AT88904864T AT88904864T ATE78169T1 AT E78169 T1 ATE78169 T1 AT E78169T1 AT 88904864 T AT88904864 T AT 88904864T AT 88904864 T AT88904864 T AT 88904864T AT E78169 T1 ATE78169 T1 AT E78169T1
- Authority
- AT
- Austria
- Prior art keywords
- insulin
- function
- liver
- targeted
- encapsulated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/143,180 US4863896A (en) | 1984-05-03 | 1988-01-13 | Diabetic control by combined insulin forms |
| EP88904864A EP0358709B1 (de) | 1988-01-13 | 1988-05-13 | Behandlung von diabetes durch kombinierte insulinformen |
| PCT/US1988/001536 WO1989006540A1 (en) | 1988-01-13 | 1988-05-13 | Diabetic control by combined insulin forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE78169T1 true ATE78169T1 (de) | 1992-08-15 |
Family
ID=22502938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT88904864T ATE78169T1 (de) | 1988-01-13 | 1988-05-13 | Behandlung von diabetes durch kombinierte insulinformen. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4863896A (de) |
| EP (1) | EP0358709B1 (de) |
| AT (1) | ATE78169T1 (de) |
| AU (1) | AU622370B2 (de) |
| DE (1) | DE3872878T2 (de) |
| DK (1) | DK452289A (de) |
| FI (1) | FI894376A0 (de) |
| WO (1) | WO1989006540A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5420108A (en) * | 1992-09-14 | 1995-05-30 | Shohet; Isaac H. | Method of controlling diabetes mellitus |
| WO1999016425A1 (en) * | 1997-09-30 | 1999-04-08 | The Ohio State University | Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells |
| US7169410B1 (en) * | 1998-05-19 | 2007-01-30 | Sdg, Inc. | Targeted liposomal drug delivery system |
| US6159931A (en) * | 1998-09-29 | 2000-12-12 | The Ohio State University | Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells |
| US6867183B2 (en) | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US7196059B2 (en) | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| AU2003236521A1 (en) * | 2002-06-13 | 2003-12-31 | Nobex Corporation | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus |
| NZ541058A (en) | 2003-01-06 | 2008-06-30 | Emisphere Tech Inc | Night-time oral insulin therapy |
| US20050203001A1 (en) | 2004-03-05 | 2005-09-15 | Emisphere Technologies, Inc. | Oral insulin therapies and protocol |
| CN102293746A (zh) * | 2003-09-09 | 2011-12-28 | 吉里德科学公司 | 治疗性脂质体 |
| CN103223160B (zh) * | 2004-07-19 | 2015-02-18 | 比奥孔有限公司 | 胰岛素-低聚物共轭物,制剂及其用途 |
| US20110135725A1 (en) | 2005-05-23 | 2011-06-09 | Sdg, Inc. | Lipid Construct for Delivery of Insulin to a Mammal |
| PL1883394T3 (pl) * | 2005-05-23 | 2018-09-28 | Sdg, Inc. | Konstrukt lipidowy do dostarczania insuliny ssakowi |
| US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| US9241908B2 (en) | 2007-10-16 | 2016-01-26 | Biocon Limited | Orally administrable solid pharmaceutical composition and a process thereof |
| US20120035105A1 (en) * | 2009-01-09 | 2012-02-09 | Sdg, Inc. | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments |
| BRPI1007457A2 (pt) | 2009-01-28 | 2015-08-25 | Smartcells Inc | Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba. |
| JP2012516342A (ja) | 2009-01-28 | 2012-07-19 | スマートセルズ・インコーポレイテツド | 結晶性インスリン複合体 |
| WO2010088286A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Synthetic conjugates and uses thereof |
| CA2750223A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Exogenously triggered controlled release materials and uses thereof |
| CA2754950A1 (en) | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
| EP2408470A4 (de) | 2009-03-20 | 2012-08-29 | Smartcells Inc | Lösliche nichtdepot-insulinkonjugate und ihre verwendung |
| US9068013B2 (en) | 2010-07-28 | 2015-06-30 | Smart Cells, Inc. | Recombinant lectins, binding-site modified lectins and uses thereof |
| EP2598170A4 (de) | 2010-07-28 | 2016-07-06 | Smartcells Inc | Arzneimittel-liganden-konjugate, deren synthese und zwischenprodukte daraus |
| US9074015B2 (en) | 2010-07-28 | 2015-07-07 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
| AU2014329567B2 (en) | 2013-10-04 | 2019-07-25 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
| SG11201908052PA (en) | 2017-03-13 | 2019-09-27 | Sdg Inc | Lipid-based nanoparticles with enhanced stability |
| US11077173B2 (en) | 2017-03-13 | 2021-08-03 | Sdg, Inc. | Lipid-based nanoparticles and methods using same |
| WO2020210697A1 (en) * | 2019-04-12 | 2020-10-15 | Sdg, Inc. | Lipid-based nanoparticles and use of same in optimized insulin dosing regimens |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4377567A (en) * | 1978-10-02 | 1983-03-22 | The Procter & Gamble Company | Lipid membrane drug delivery |
| US4603044A (en) * | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
-
1988
- 1988-01-13 US US07/143,180 patent/US4863896A/en not_active Expired - Lifetime
- 1988-05-13 AU AU17905/88A patent/AU622370B2/en not_active Ceased
- 1988-05-13 EP EP88904864A patent/EP0358709B1/de not_active Expired - Lifetime
- 1988-05-13 WO PCT/US1988/001536 patent/WO1989006540A1/en not_active Ceased
- 1988-05-13 DE DE8888904864T patent/DE3872878T2/de not_active Expired - Lifetime
- 1988-05-13 AT AT88904864T patent/ATE78169T1/de not_active IP Right Cessation
-
1989
- 1989-09-13 DK DK452289A patent/DK452289A/da not_active Application Discontinuation
- 1989-09-15 FI FI894376A patent/FI894376A0/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0358709A1 (de) | 1990-03-21 |
| AU1790588A (en) | 1989-08-11 |
| DE3872878D1 (de) | 1992-08-20 |
| FI894376A0 (fi) | 1989-09-15 |
| EP0358709B1 (de) | 1992-07-15 |
| AU622370B2 (en) | 1992-04-02 |
| WO1989006540A1 (en) | 1989-07-27 |
| EP0358709A4 (de) | 1990-03-08 |
| US4863896A (en) | 1989-09-05 |
| DK452289D0 (da) | 1989-09-13 |
| DE3872878T2 (de) | 1992-12-03 |
| DK452289A (da) | 1989-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3872878D1 (de) | Behandlung von diabetes durch kombinierte insulinformen. | |
| Harris | Iontophoresis: clinical research in musculoskeletal inflammatory conditions | |
| DK0527835T3 (da) | Doseringsform til afgivelse af et anti-Parkinsonmiddel | |
| DK0480934T3 (da) | Lægemiddel, der indeholder ephedrin og koffein til behandling af overvægt | |
| NO944249L (no) | Transdermal administrering av oksybutynin | |
| ES2186693T3 (es) | Uso combinado del acido hialuronico y de agentes terapeuticos para mejorar el efecto terapeutico. | |
| KR910005858A (ko) | 지방산 요법 | |
| SE8204874D0 (sv) | Farmaceutiska preparat, innefattande humant insulin och humant proinsulin | |
| SLOCUMB et al. | Diagnosis, treatment and prevention of chronic hypercortisonism in patients with rheumatoid arthritis | |
| KR100271087B1 (en) | Protein synthesis stimulator comprising tcf-2 for the treatment of hypoproteinemia | |
| PT651654E (pt) | Utilizacao de um dimero de lisozima para a preparacao de um medicamento para modular os mecanismos natutais de defesa | |
| AR003979A1 (es) | Administracion transdermica de vorozol. | |
| Rosenthal | Alterations in serum thyroxine with cerebral electrotherapy (electrosleep) | |
| AR029160A1 (es) | El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo | |
| EA199800770A1 (ru) | Лекарственный препарат для терапевтического лечения вирусного гепатита | |
| ATE66375T1 (de) | Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung. | |
| RU94000695A (ru) | Средство с противоаллергическим действием | |
| KR900701311A (ko) | 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법 | |
| AR008155A1 (es) | Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres. | |
| SE9101341D0 (sv) | New medicinal use | |
| GB2019720A (en) | S-adenosyl-L-homocysteine and salts thereof for use in therapy | |
| JPS6016921A (ja) | 貼付薬 | |
| DE60120371D1 (de) | Verwendung von wachstumshormon in niederen dosen | |
| Kennedy | Captopril in the treatment of chronic CHF | |
| 徐济民 et al. | ANTIARRHYTHMIC ACTION OF CHANGROLIN ADMINISTERED BY CONTINUOUS INTRAVENOUS INFUSION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |